AnaptysBio looks ahead to other indications after Phase II miss in palmoplantar pustulosis

Following a Phase II miss for imsidolimab to treat palmoplantar pustulosis, AnaptysBio will look ahead to five other indications for the IL-36R antagonist.

The company plans to bring imsidolimab (ANB019) into Phase III testing mid-year for generalized pustular psoriasis (GPP), where IL-36 signaling has a clearer role in driving disease. ...